From Gross to Net Estimates to IPR&D and intangible assets to Revenue Recognition examples, M&A Trends, Complex Debt and Equity Structures in Life Sciences, Tax News, ESG, Regulatory Updates, Joint Ventures: Accounting Considerations and latest updates, this conference will address the latest developments in key areas. You’ll hear from experts at Deloitte, Ernst & Young, Effectus Group, life science analysts, and your industry counterparts.
LEARNING OBJECTIVES:
- Understand the latest accounting changes in key areas
- Recognize the timelines and key factors affecting the life science industry
- Begin to assess the effects of these standards on your company or clients
Agenda
Agenda: DAY 1
8:45 - 10:05 - Accounting for R&D and Clinical Trials
- R&D Funding Arrangements
- R&D Cost Classifications
- Other Intangible Assets
- SEC Comment Letter Trends
10:05 - 10:30 - Break
10:30 - 11:30 - Tax Update
- Latest legislative developments
- Key Tax Proposals
- Build Back Better Act Observations
- Possible timing and other legislative priorities
11:30 - 12:15 - Lunch Break
12:15 - 1:35 - Revenue Recognition: ASC 606 Practical Issues - Life Sciences
- Scope of Contract
- Performance Obligations
- Nature of promise: sales of points
- Collaboration agreements
- Sales using third-party platforms
- Gross vs Net
- Counterparty Perspective
1:35 - 1:50 - Break
1:50 - 3:05 - M&A in Life Sciences
- Industry Trends
- Accounting Considerations
3:10 - 4:40 - IPR&D and Intangible Assets
- Accounting Insights
Agenda: DAY 2
8:45 - 10:15 - Convertible Debt
- Accounting Considerations
- When should companies consider convertible debt?
- Convertible structure in the life science financing cycle
- Changes of control, tax implications, size, maturity, and other questions
10:15 - 10:30 - Break
10:30 - 12:00 - Joint Ventures, Consolidations and VIEs: Accounting Considerations
- Consolidation of controlled subsidiaries
- Equity method investments
- Financial assets
12:00 - 12:30 - Lunch Break
12:30 - 1:40 - ESG
- ESG Landscape: Regulatory Developments
- Operationalizing ESG & Sustainability
- Disclosure Trends in Life Sciences Industry
- Taking Action
1:40 - 1:45 - Break
1:45 - 3:15 - Regulatory Update
- Update on SEC Proposed Rule: Cybersecurity Risk Management, Strategy Governance and Incident Disclosure
- Market Trends
- SEC Requirements Explained
- ESG
- Adoption Timeline
- The Framework
- Disclosure Examples
- Financial Accounting Update
- FASB Project Update
- ASUs
- Issues on the horizon
3:15 - 3:25 - Break
3:25 - 4:45 - Gross to Net
- Introduction and Overview
- Industry View
- Estimation Methodology
- Approaching Launch
- Key Challenges
- SEC Comments
- Close and Financial Reporting
- GTN Hot Topics Discussion
Speakers
- Nathan Mitchell Deloitte, Partner
- Phil Howard Ernst & Young, Partner
- Andrew Lineback Ernst & Young, Senior Manager
- Nick Lubold Deloitte, Manager
- Jenna Tarapani Deloitte, Senior Manager
- Christie Hutchinson Effectus Group, Director
- Travis Combs Effectus Group, Managing Director
- Rochelle Tsui Ernst & Young, Manager
- Tim Geringer Ernst & Young, Senior Manager
- Aleks Zabreyko Connor Group, Managing Partner
- Jeffrey Kummer Deloitte, Director of Tax Policy
- Randa Ghantous Connor Group, Partner
- Kevin Dougherty Deloitte, Tax Partner
- Eli Seller Effectus Group, Managing Director, Technical Accounting & IPO
